News archive
Showing 702 results
June 2018
-
Media Release
Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
- The My Migraine Voice survey involved more than 11,000 people globally, 10% of which were from the US, and highlights urgent need for better care for benefit of patients and society- In the US,… -
Media Release
Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
-
Media Release
Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community
- STEP (Solutions to Empower Patients)™ Program helps nonprofit organizations deliver innovative solutions to patient communities - Funded programs aim to improve the experience of people living… -
Media Release
Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community
-
Media Release
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
- New prescribing information to include data demonstrating Cosentyx® (secukinumab) slows progression of joint structural damage associated with psoriatic arthritis (PsA) at Week 24(1)- PsA can lead… -
Media Release
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
-
Media Release
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable (1)Patients had a 65% chance of being relapse-free… -
Media Release
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
-
Media Release
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)-- About two-thirds of… -
Media Release
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Media Release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
- Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line… -
Media Release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer